Late-onset neuromyelitis optica spectrum disorder: A case series from Iran - 02/04/22
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Introduction |
Neuromyelitis optica spectrum disorder (NMOSD) is a disabling autoimmune disease of the central nervous system that can start at ages of 50 or more, when it is called late-onset NMOSD (LO-NMOSD). Data on this disorder are sparse. In this cross-sectional study, patient characteristics of the disease were studied. LO-NMOSD patients of a tertiary center in Tehran were studied from 2016 to 2020.
Case reports |
Eight patients were identified, half of whom were men. The diagnostic delay was from no time-lapse to three years (mean: 0.62, SD: 1.06), which was significantly shorter than in early-onset patients. Seven patients (87.5%) tested positive for AQP4-IgG which was significantly higher compared to early-onset patients (p-value=0.01). Four patients (50%) had both transverse myelitis and optic neuritis as presenting symptoms, while three (38%) had just myelitis and only one (12%) had optic neuritis.
Conclusion |
There is discrepancy regarding different aspects of LO-NMOSD. Further studies are needed to clarify the subject in order to enhance diagnosis and treatment.
Le texte complet de cet article est disponible en PDF.Keywords : Neuromyelitis optica spectrum disorder, Late-onset, Iran
Plan
Vol 178 - N° 3
P. 249-252 - mars 2022 Retour au numéro
Article précédent
- Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial
- M. Michel, E. Le Page, D.A. Laplaud, R. Wardi, C. Lebrun, F. Zagnoli, S. Wiertlewski, M. Coustans, G. Edan, K. Chevreul, D. Veillard, West Network for Excellence in Neuroscience, The COPOUSEP investigators, F. Lallement, M. Cohen, C. Blanchard, E. Sartori, O. Demarco, F. Rouhart, C. Papeix, G. Taurin, T. Anani, P. Kassiotis, C. Hamon, M.A. Lester, M. Merienne
- Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: A prospective study
- J. Rigal, D. Biotti, Z. Lépine, J. Ciron
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?